Phase I trial with a combination of docetaxel +153 Sm-EDTMP (Samarium 153) [samarium-153 SM lexidronam] in patients with hormone-refractory prostate cancer

Trial Profile

Phase I trial with a combination of docetaxel +153 Sm-EDTMP (Samarium 153) [samarium-153 SM lexidronam] in patients with hormone-refractory prostate cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Dec 2008

At a glance

  • Drugs Docetaxel; Samarium-153-SM-lexidronam
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Dec 2008 Planned patient number changed from 12 to 13 as reported by ClinicalTrials.gov.
    • 16 Dec 2008 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top